NanoValent Pharmaceuticals, Inc.
Biotechnology ResearchMontana, United States2-10 Employees
NanoValent Pharmaceuticals is a privately held company that collaborates closely with US-based and international academic and industry partners. We’re dedicated to developing novel treatment options that bring us closer to a potential cure for hard-to-treat cancers and hematological malignancies. Using our unique, highly optimized platform technology, we are developing Novel Format Conjugates called nano-ADC-like Targeted Nanospheres (nADC/TNS). These targeted agents, with superior cancer selectivity and the ability to deliver higher doses, significantly improve the delivery, safety, and efficacy of both existing and novel anticancer therapeutics, while reducing toxicity by targeting malignant cells more specifically and sparing normal, healthy tissues. Our proprietary technology enables us to easily develop a broad pipeline of future, first-in-class nADC/TNS with different antibody targeting and payload combinations, which can deliver much higher and more effective payloads than traditional Antibody-drug Conjugates (ADCs), thereby revolutionizing and vastly improving anticancer treatment. Due to its ability to cross the blood-brain barrier (BBB), our nADC/TNS offers significant lateral opportunities beyond oncology, in neurological diseases. The power of our platform is best demonstrated by our lead investigational product, NV103/NV105, which is approaching potential IND status and has strong data in CD99-expressing tumor models, including glioblastoma, pancreatic, ovarian, and Ewing Sarcoma. The initial focus of NV103/NV105 on Ewing Sarcoma demonstrates our strong commitment to advancing the potential of nADC/TNS in pediatric cancers, thereby more fully exploiting the benefits of our platform technology.
1-888-653-2347 
support@leadiq.com 
